Average Co-Inventor Count = 8.81
ph-index = 5
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Theravance, Inc. (12 from 386 patents)
2. Novartis Ag (8 from 3,923 patents)
3. Theravance Biopharma R&d Ip, LLC (3 from 262 patents)
23 patents:
1. 12129246 - Hydroquinazoline derivatives for the treatment of a disease or disorder
2. 12122761 - 2-azaspiro[3.4]octane derivatives as M4 agonists
3. 11820778 - 2-azaspiro[3.4]octane derivatives as M4 agonists
4. 11548865 - 2-azaspiro[3.4]octane derivatives as M4 agonists
5. 11485742 - 2-azaspiro[3.4]octane derivatives as M4 agonists
6. 9676728 - 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof
7. 9475806 - Complement factor B inhibitors and uses there of
8. 9198899 - Dual-acting benzoimidazole antihypertensive agents
9. 9150514 - Dual-acting antihypertensive agents
10. 9056874 - Complement pathway modulators and uses thereof
11. 8895755 - Intermediates for preparing dual-acting benzyl triazole antihypertensive agents having angiotensin II type I receptor antagonist activity and neprilysin-inhibition activity
12. 8735625 - Dual-acting antihypertensive agents
13. 8637676 - Dual-acting benzoimidazole antihypertensive agents
14. 8569351 - Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activity
15. 8394846 - Dual-acting antihypertensive agents